logo

Ascendis Pharma A/S (ASND)



Trade ASND now with
  Date
  Headline
1/8/2018 8:28:54 AM Ascendis Updates On Rare Disease Endocrinology Pipeline And Presents Initial Phase 1 Data For TransCon PTH
11/29/2017 6:27:53 AM Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $62 Price Target
11/29/2017 6:26:54 AM Wedbush Is Lowering Ascendis Pharma A/S (ASND) 2018 Estimate To -3.53 From -2.81
11/29/2017 6:26:34 AM Wedbush Is Cutting Ascendis Pharma A/S (ASND) Q4 18 Estimate To -0.91 From -0.72
11/29/2017 6:26:21 AM Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q3 18 Estimate To -0.89 From -0.71
11/29/2017 6:26:08 AM Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q2 18 Estimate To -0.87 From -0.70
11/29/2017 6:25:54 AM Wedbush Is Lowering Ascendis Pharma A/S (ASND) Q1 18 Estimate To -0.86 From -0.68
11/29/2017 6:25:33 AM Wedbush Is Cutting Ascendis Pharma A/S (ASND) 2017 Estimate To -3.60 From -3.05
11/29/2017 6:25:10 AM Wedbush Is Cutting Ascendis Pharma A/S (ASND) Q4 17 Estimate To -0.85 From -0.68
11/29/2017 6:24:29 AM Wedbush Is Cutting Ascendis Pharma A/S (ASND) 2018 Rev. Estimate To 1.7 M From 1.8 M
11/16/2017 4:05:01 PM Ascendis Pharma A/S Q3 Loss/share EUR 1.04 Vs. Loss EUR 0.72 Year Ago
9/28/2017 7:59:26 AM Wedbush Reiterates Ascendis Pharma A/S (ASND) At Outperform With $62 Price Target
9/28/2017 7:57:58 AM Wedbush Is Increasing Ascendis Pharma A/S (ASND) 2018 Estimate To -2.81 From -3.15
9/28/2017 7:57:44 AM Wedbush Is Raising Ascendis Pharma A/S (ASND) 4Q18 Estimate To -0.72 From -0.81
9/28/2017 7:57:32 AM Wedbush Is Raising Ascendis Pharma A/S (ASND) 3Q18 Estimate To -0.71 From -0.79
9/28/2017 7:57:21 AM Wedbush Is Raising Ascendis Pharma A/S (ASND) 2Q18 Estimate To -0.70 From -0.78
9/28/2017 7:57:05 AM Wedbush Is Increasing Ascendis Pharma A/S (ASND) 1Q18 Estimate To -0.68 From -0.77
9/28/2017 7:56:45 AM Wedbush Is Increasing Ascendis Pharma A/S (ASND) 2017 Estimate To -3.05 From -3.25